SOPHiA GENETICS SA (SOPH)
| Previous Close | 4.6300 |
| Open | 4.7000 |
| Bid | 3.4000 x 900 |
| Ask | 5.2000 x 1100 |
| Day's Range | 4.4000 - 4.9900 |
| 52 Week Range | 1.6850 - 8.0400 |
| Volume | |
| Avg. Volume | 133,772 |
| Market Cap | 319.128M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Acutis Diagnostics Leverages SOPHiA GENETICS Technology to Create New Next Generation Sequencing Test
BOSTON & LAUSANNE, Switzerland, March 28, 2023--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Acutis Diagnostics, a specialized medical laboratory, will use SOPHiA DDM™ to develop a new genomic assay. This new next-generation sequencing (NGS) test will build on Acutis Diagnostics’ track record of approved lab-developed tests that support clinical trials, cancer research and treatment.
- Business Wire
SOPHiA GENETICS and Agilent Partner on Comprehensive Solution for Cancer Analysis
BOSTON & LAUSANNE, Switzerland, March 14, 2023--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and the leader in data-driven medicine, is partnering with Agilent to offer a comprehensive solution for cancer analysis.
- Business Wire
SOPHiA GENETICS Reports Fourth Quarter and Year End 2022 Financial Results
BOSTON & LAUSANNE, Switzerland, March 07, 2023--SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced financial results for its fourth quarter and full fiscal year ended December 31, 2022.
